Canada: A Paradigm Shift in Patent Law

This article first appeared in the April issue of Managing Intellectual Property, Life Science Focus 2006.

Recent disputes between research-based pharma companies and generics have addressed the viability of use patents in PMNOC proceedings. Bill Richardson of McCarthy Tétrault LLP examines the cases and asks whether the Regulations need to be changed.

A paradigm shift in patent law?

Patent law is based on a compact between the patentee and the public in which the patentee receives a limited monopoly in return for providing a new, useful invention whose content is open to the public. A patent, however, is not necessarily a new thing. It does not have to be a new mechanical device or a chemical composition. Instead, a patent can be a new beneficial use or indication for a previously known mechanism, object or compound (see, for example, Shell Oil Co v Commissioner of Patents (1982), 67 CPR (2d) 1 (SCC)). In the pharmaceutical industry, the public gain from "new use patents" is well-documented as they have been a main driving force for pharmaceutical innovators to research new treatments, cures and preventions based on pre-existing drugs. For instance, many of the medications on the market for arthritis were originally designed to treat other illnesses. To cite a recent example, in March 2006, the US Food and Drug Administration approved Rituxan, a drug used to treat non-Hodgkin’s lymphoma since 1998, to treat rheumatoid arthritis in patients who had not responded to conventional therapies. In many cases, these new uses for old chemical compounds become the gold standard for previously untreatable patients.

Use patents: a balanced approach to infringing use

A pharmaceutical innovator can prevent a generic drug from being marketed if the innovator can prove that members of the public would use the drug for the new use that is covered by a valid patent. In the leading case in this area, Procter & Gamble Pharmaceuticals Canada Inc v Canada, [2003] 1 FC 402 (FCA), the generic manufacturer (Genpharm) alleged that its product would not infringe P & G's patent for a new way of using an existing drug (etidronate) for the treatment of osteoporosis. Although Genpharm assured the court that its generic etidronate would not be used for this new indication, P & G put forward evidence that, inter alia:

    1. some pharmacists would interchange the etidronate drugs for all uses;
    2. if the etidronate drugs were interchanged in a manner that constituted infringing use, Genpharm would not take any positive action to stop this infringing use;
    3. Genpharm's product monograph did not include any precaution against the infringing use and, in fact, included bioequivalent studies with the intermittent cycle use product (covered by the use patent).

Based on this evidence, the Court found that Genpharm's intentions and actions would inevitably lead to infringing use by third parties. In this regard, the Federal Court of Appeal held that a generic manufacturer infringed an innovator's use patent if there was evidence that the innovator's patent would be infringed by third parties, such as patients or pharmacists, even if there was no express inducement or procurement by the generic producer. In the words of Justice Rothstein (as he then was), if a generic markets a product and there will be unlawful use of that product by members of the public,

that is the infringement the Regulations are intended to preclude. There is no suggestion that the generic producer must have induced or procured patients or others to infringe the patent. For this reason, I am satisfied that in the case of use claims, it is not necessary for a pantentee to demonstrate that a generic producer's actions will induce or procure patent infringement by patients or others.

Soon after the Procter and Gamble decision was rendered, Justice Rothstein and the Federal Court of Appeal once again had an opportunity to consider the disconnect between a generic manufacturer's assurances of non-infringing use in the NOC proceedings and the reality of infringing use in the marketplace after the NOC was issued. In Genpharm v AB Hassle, (2004) 38 CPR (4th) 17 (FCA), the Court had to consider whether Genpharm's omeprazole drug for (ostensibly) treating stomach acid secretion would, in fact, infringe a use patent for omeprazole in which it was used to treat stomach bacteria. As in the earlier etidronate proceeding, Genpharm assured the court that it would not be marketing its omeprazole to treat stomach bacteria.

In considering the veracity of this submission, Rothstein J. focused on the fact that, in the original Product Monograph filed in the NOC Proceeding, Genpharm only referred to treating stomach acid. However, after all the evidence had been filed in the NOC Proceeding, Genpharm amended its Product Monograph to include studies relating to stomach bacteria infections. When asked to explain this ex post amendment, Genpharm's response was circumscribed: it stipulated that it would label and market its omeprazole simply for treating acid indigestion and that it would not induce any infringement. Not surprisingly, the Court of Appeal was not satisfied with this response and held that – since the facts indicated that Genpharm's omeprazole drug would be used for treating stomach bacteria by third parties – Genpharm was prohibited from selling or marketing the drug until the term of the use patent had expired.

Proof of infringing use: an innovator's burden

The courts, however, have been careful to emphasize that there is a positive burden on the innovator to demonstrate that, if the generic drug entered the marketplace, third parties would in fact infringe the innovator's use patent. Mere speculation is not sufficient. Instead, as held in AB Hassle v Canada (Minister of National Health and Welfare), (2002) 22 CPR (4th) 1 (FCA), the innovator has to submit concrete facts that the marketing of a generic drug would infringe a use patent vis-à-vis the unlawful use by members of the public.

This balanced approach, in which the courts will only prohibit generics from entering the marketplace in circumstances where the innovator can prove that the use patent would be infringed by third parties, is critical to the viability of use patents. Otherwise, a generic manufacturer could simply make bald assertions in the NOC proceeding that its drug will only be promoted for non-patented uses and then, after the Notice of Compliance has been issued, simply turn a blind eye (or give a gentle nudge) to unauthorized uses by third parties. Indeed, the problem is exacerbated by the fact that provincial formularies often provide incentives for doctors and pharmacists to exchange generics for innovator drugs with little or no guidance concerning the appropriate legal uses (see, for example, Astrazeneca Canada Inc v Apotex Inc, [2006] MJ No 38 (Mn Ct A)). In this regard, a brief word on provincial formularies is warranted.

Provincial formularies

After Health Canada issues a Notice of Compliance, the drug then gets registered on provincial formularies. These formularies are governed by various provincial legislation and regulations that determine which drugs can be interchanged and the level of their maximum price. Under some provincial formularies, pharmacists are required to substitute the lowest-priced interchangeable drug in the formulary unless a doctor specifically writes a "no substitution" script. Further, at least in Ontario, the price of the drug sets the amount of reimbursement to the pharmacist if the drug is dispensed to selected categories of customers, such as senior citizens (see Apotex v Ontario (Minister of Health), (2002) 17 CPR (4th) 1 at para 2 (Ont Ct A)). In this context, bioequivalent drugs are frequently interchanged in an unfettered manner without any limitation on approved uses.

Accordingly, it is not surprising that — contrary to their assurances during the NOC proceedings — a number of generic drug manufacturers have attempted to have their drugs listed on drug formularies as completely interchangeable, even though their legal ability to sell the drug is circumscribed to specific non-patented uses.

The most notable example of this occurred in Apotex v Ontario (Minister of Health), (2002) 17 CPR (4th) 1 (Ont Ct A), in which Pfizer marketed sertraline for the treatment of depression, compulsive disorder and panic disorder. While Pfizer's patent for the treatment of depression expired, it still held use patents for compulsive disorder and panic disorder. In serving its Notice of Allegation, Apotex alleged that it would not make, construct, use, or sell sertraline for the valid patented uses. As a result, Pfizer did not file a Notice of Allegation, but allowed Apotex to enter the market solely to treat depression, and a Notice of Compliance was issued by Health Canada that strictly prohibited Apotex from selling sertraline for compulsive disorder and panic disorder (Apotex Inc v Ontario (Minister of Health) (2000) 10 CPR (4th) 166 at para 14 (Ont Sup Ct)).

Upon receiving the Notice of Compliance, Health Ontario listed Apotex's sertraline on the Ontario formulary as interchangeable strictly for the treatment of depression. Due to Apotex's limited ability to sell the drug legally, Health Ontario placed an asterisk on Apotex's sertraline listing on the formulary specifying that it was only for the treatment of depression. In response to this indication of limited use, the president of Apotex sent a letter to the pharmacists of Ontario in which he urged pharmacists to dispense Apotex's sertraline without regard to indications. Indeed, in sharp contrast with the assurances of limited use in its NOA, Sherman wrote that the Ontario Drug Benefit Formulary had taken the "unprecedented step" of stating that

interchangeability is for treatment of depression, thus suggesting non-interchangeability for other uses. ... This statement by the Ministry is not only unprecedented, but unlawful. ... Why has the Ministry done this? It appears that Pfizer has told the Ministry that use of generic products other than for depression would violate Pfizer's patents for such indications. It is irresponsible for the Ministry to submit to such pressure from Pfizer (Apotex v Ontario (Minister of Health), 10 CPR (4th) 166 at para 17 (Ont Sup Ct).

Soon thereafter, Apotex brought an application for judicial review to force the Ontario Formulary to remove the restriction on the interchangeable use of sertraline, despite the fact that it was only allowed to be sold for depression pursuant to Health Canada's NOC. Both the Divisional Court and the Ontario Court of Appeal rejected Apotex's arguments, holding that Apotex's sertraline was only legally sold to treat depression and that Apotex's attempt to sell sertraline for other disorders would be illegal and in breach of the Canada Food and Drugs Act . In short, the courts of Ontario held that it was well within the government's rights that the formulary for interchangeable drugs only lists those drugs that are legal to sell (Apotex v Ontario (Minister of Health), (2002) 17 CPR (4th) 1 at paras 13-14 (Ont Ct A)).

Changes to the PMNOC Regulations: unfairly tipping the scales?

On December 11 2004, the Canadian government published proposed changes, inter alia, to the Patented Medicines (Notice of Compliance) Regulations (NOC Regulations) under the Patent Act. One of the proposed amendments would allow a generic company a new ground in its Notice of Allegation that will potentially strike a blow to new use patents. Under proposed Section 5(1)(b)(v), a generic company can allege that it will not be seeking approval for a patented use. Essentially, this proposed amendment will allow a generic company to bypass new use patents simply by asserting that the generic will only be expressly marketing the drug for old uses. In the context of past wilful blindness by generics to infringing third party uses, coupled with the trend to make all bioequivalent drugs interchangeable on provincial formularies, innovator companies have reason to be concerned about possible abuses to the proposed amendment.

* * * * * * * * * * * * * *

William H. Richardson is a partner in the litigation department, co-chair of the intellectual property group, and industry group leader of the pharma and life sciences practices at McCarthy Tétrault. Richardson specializes in trial and appellate advocacy, as well as ADR, focused exclusively on intellectual property. He has been counsel on a number of the largest IP cases in Canada, and, consistent with the nature of intellectual property, is frequently consulted on multi-jurisdictional disputes.

Richardson represents clients from a broad range of industries including broadcasting, publishing, entertainment, consumer home and personal care products, foods, pharmaceuticals, biotechnology, petrochemical/energy, internet, clothing and footwear and automotive. He is on the Board of Directors of Street Kids International, a Canadian not-for-profit specializing in the education, support and survival of street youth around the world.

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

To print this article, all you need is to be registered on

Click to Login as an existing user or Register so you can print this article.

In association with
Related Video
Up-coming Events Search
Font Size:
Mondaq on Twitter
Register for Access and our Free Biweekly Alert for
This service is completely free. Access 250,000 archived articles from 100+ countries and get a personalised email twice a week covering developments (and yes, our lawyers like to think you’ve read our Disclaimer).
Email Address
Company Name
Confirm Password
Mondaq Topics -- Select your Interests
 Law Performance
 Law Practice
 Media & IT
 Real Estate
 Wealth Mgt
Asia Pacific
European Union
Latin America
Middle East
United States
Worldwide Updates
Mondaq Ltd requires you to register and provide information that personally identifies you, including what sort of information you are interested in, for three primary purposes:
  • To allow you to personalize the Mondaq websites you are visiting.
  • To enable features such as password reminder, newsletter alerts, email a colleague, and linking from Mondaq (and its affiliate sites) to your website.
  • To produce demographic feedback for our information providers who provide information free for your use.
  • Mondaq (and its affiliate sites) do not sell or provide your details to third parties other than information providers. The reason we provide our information providers with this information is so that they can measure the response their articles are receiving and provide you with information about their products and services.
    If you do not want us to provide your name and email address you may opt out by clicking here
    If you do not wish to receive any future announcements of products and services offered by Mondaq you may opt out by clicking here

    Terms & Conditions and Privacy Statement (the Website) is owned and managed by Mondaq Ltd and as a user you are granted a non-exclusive, revocable license to access the Website under its terms and conditions of use. Your use of the Website constitutes your agreement to the following terms and conditions of use. Mondaq Ltd may terminate your use of the Website if you are in breach of these terms and conditions or if Mondaq Ltd decides to terminate your license of use for whatever reason.

    Use of

    You may use the Website but are required to register as a user if you wish to read the full text of the content and articles available (the Content). You may not modify, publish, transmit, transfer or sell, reproduce, create derivative works from, distribute, perform, link, display, or in any way exploit any of the Content, in whole or in part, except as expressly permitted in these terms & conditions or with the prior written consent of Mondaq Ltd. You may not use electronic or other means to extract details or information about’s content, users or contributors in order to offer them any services or products which compete directly or indirectly with Mondaq Ltd’s services and products.


    Mondaq Ltd and/or its respective suppliers make no representations about the suitability of the information contained in the documents and related graphics published on this server for any purpose. All such documents and related graphics are provided "as is" without warranty of any kind. Mondaq Ltd and/or its respective suppliers hereby disclaim all warranties and conditions with regard to this information, including all implied warranties and conditions of merchantability, fitness for a particular purpose, title and non-infringement. In no event shall Mondaq Ltd and/or its respective suppliers be liable for any special, indirect or consequential damages or any damages whatsoever resulting from loss of use, data or profits, whether in an action of contract, negligence or other tortious action, arising out of or in connection with the use or performance of information available from this server.

    The documents and related graphics published on this server could include technical inaccuracies or typographical errors. Changes are periodically added to the information herein. Mondaq Ltd and/or its respective suppliers may make improvements and/or changes in the product(s) and/or the program(s) described herein at any time.


    Mondaq Ltd requires you to register and provide information that personally identifies you, including what sort of information you are interested in, for three primary purposes:

    • To allow you to personalize the Mondaq websites you are visiting.
    • To enable features such as password reminder, newsletter alerts, email a colleague, and linking from Mondaq (and its affiliate sites) to your website.
    • To produce demographic feedback for our information providers who provide information free for your use.

    Mondaq (and its affiliate sites) do not sell or provide your details to third parties other than information providers. The reason we provide our information providers with this information is so that they can measure the response their articles are receiving and provide you with information about their products and services.

    Information Collection and Use

    We require site users to register with Mondaq (and its affiliate sites) to view the free information on the site. We also collect information from our users at several different points on the websites: this is so that we can customise the sites according to individual usage, provide 'session-aware' functionality, and ensure that content is acquired and developed appropriately. This gives us an overall picture of our user profiles, which in turn shows to our Editorial Contributors the type of person they are reaching by posting articles on Mondaq (and its affiliate sites) – meaning more free content for registered users.

    We are only able to provide the material on the Mondaq (and its affiliate sites) site free to site visitors because we can pass on information about the pages that users are viewing and the personal information users provide to us (e.g. email addresses) to reputable contributing firms such as law firms who author those pages. We do not sell or rent information to anyone else other than the authors of those pages, who may change from time to time. Should you wish us not to disclose your details to any of these parties, please tick the box above or tick the box marked "Opt out of Registration Information Disclosure" on the Your Profile page. We and our author organisations may only contact you via email or other means if you allow us to do so. Users can opt out of contact when they register on the site, or send an email to with “no disclosure” in the subject heading

    Mondaq News Alerts

    In order to receive Mondaq News Alerts, users have to complete a separate registration form. This is a personalised service where users choose regions and topics of interest and we send it only to those users who have requested it. Users can stop receiving these Alerts by going to the Mondaq News Alerts page and deselecting all interest areas. In the same way users can amend their personal preferences to add or remove subject areas.


    A cookie is a small text file written to a user’s hard drive that contains an identifying user number. The cookies do not contain any personal information about users. We use the cookie so users do not have to log in every time they use the service and the cookie will automatically expire if you do not visit the Mondaq website (or its affiliate sites) for 12 months. We also use the cookie to personalise a user's experience of the site (for example to show information specific to a user's region). As the Mondaq sites are fully personalised and cookies are essential to its core technology the site will function unpredictably with browsers that do not support cookies - or where cookies are disabled (in these circumstances we advise you to attempt to locate the information you require elsewhere on the web). However if you are concerned about the presence of a Mondaq cookie on your machine you can also choose to expire the cookie immediately (remove it) by selecting the 'Log Off' menu option as the last thing you do when you use the site.

    Some of our business partners may use cookies on our site (for example, advertisers). However, we have no access to or control over these cookies and we are not aware of any at present that do so.

    Log Files

    We use IP addresses to analyse trends, administer the site, track movement, and gather broad demographic information for aggregate use. IP addresses are not linked to personally identifiable information.


    This web site contains links to other sites. Please be aware that Mondaq (or its affiliate sites) are not responsible for the privacy practices of such other sites. We encourage our users to be aware when they leave our site and to read the privacy statements of these third party sites. This privacy statement applies solely to information collected by this Web site.

    Surveys & Contests

    From time-to-time our site requests information from users via surveys or contests. Participation in these surveys or contests is completely voluntary and the user therefore has a choice whether or not to disclose any information requested. Information requested may include contact information (such as name and delivery address), and demographic information (such as postcode, age level). Contact information will be used to notify the winners and award prizes. Survey information will be used for purposes of monitoring or improving the functionality of the site.


    If a user elects to use our referral service for informing a friend about our site, we ask them for the friend’s name and email address. Mondaq stores this information and may contact the friend to invite them to register with Mondaq, but they will not be contacted more than once. The friend may contact Mondaq to request the removal of this information from our database.


    From time to time Mondaq may send you emails promoting Mondaq services including new services. You may opt out of receiving such emails by clicking below.

    *** If you do not wish to receive any future announcements of services offered by Mondaq you may opt out by clicking here .


    This website takes every reasonable precaution to protect our users’ information. When users submit sensitive information via the website, your information is protected using firewalls and other security technology. If you have any questions about the security at our website, you can send an email to

    Correcting/Updating Personal Information

    If a user’s personally identifiable information changes (such as postcode), or if a user no longer desires our service, we will endeavour to provide a way to correct, update or remove that user’s personal data provided to us. This can usually be done at the “Your Profile” page or by sending an email to

    Notification of Changes

    If we decide to change our Terms & Conditions or Privacy Policy, we will post those changes on our site so our users are always aware of what information we collect, how we use it, and under what circumstances, if any, we disclose it. If at any point we decide to use personally identifiable information in a manner different from that stated at the time it was collected, we will notify users by way of an email. Users will have a choice as to whether or not we use their information in this different manner. We will use information in accordance with the privacy policy under which the information was collected.

    How to contact Mondaq

    You can contact us with comments or queries at

    If for some reason you believe Mondaq Ltd. has not adhered to these principles, please notify us by e-mail at and we will use commercially reasonable efforts to determine and correct the problem promptly.

    By clicking Register you state you have read and agree to our Terms and Conditions